Chronic glutamate toxicity in neurodegenerative diseases-What is the evidence?

Frontiers in Neuroscience

Volumn 9, Issue DEC, 2015, Pages

  Lewerenz, Jan ^a   Maher, Pamela ^b  

^a UNIVERSITY OF ULM   (Germany)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Excitotoxicity; Glutamate receptors; Glutamate transporters; Huntington's disease; Neurodegeneration; System x c

Indexed keywords

GLUTAMATE RECEPTOR; GLUTAMIC ACID;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84954470044     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00469     Document Type: Review

References (241)

1. Adak, S., Wang, Q., and Stuehr, D. J. (2000). Arginine conversion to nitroxide by tetrahydrobiopterin-free neuronal nitric-oxide synthase. Implications for mechanism. J. Biol. Chem. 275, 33554-33561. doi: 10.1074/jbc.M004337200
2. Ahmadi, S., Muth-Selbach, U., Lauterbach, A., Lipfert, P., Neuhuber, W. L., and Zeilhofer, H. U. (2003). Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine. Science 300, 2094-2097. doi: 10.1126/science.1083970
3. Albano, R., Liu, X., and Lobner, D. (2013). Regulation of system x(c)-in the SOD1-G93A mouse model of ALS. Exp. Neurol. 250, 69-73. doi: 10.1016/j.expneurol.2013.09.008
4. Alexander, G. M., Deitch, J. S., Seeburger, J. L., Del Valle, L., and Heiman-Patterson, T. D. (2000). Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) Cu/Zn superoxide dismutase. J. Neurochem. 74, 1666-1673. doi: 10.1046/j.1471-4159.2000.0741666.x
5. Angulo, M. C., Kozlov, A. S., Charpak, S., and Audinat, E. (2004). Glutamate released from glial cells synchronizes neuronal activity in the hippocampus. J. Neurosci. 24, 6920-6927. doi: 10.1523/JNEUROSCI.0473-04.2004
6. Arriza, J. L., Fairman, W. A., Wadiche, J. I., Murdoch, G. H., Kavanaugh, M. P., and Amara, S. G. (1994). Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J. Neurosci. 14, 5559-5569.
7. Arzberger, T., Krampfl, K., Leimgruber, S., and Weindl, A. (1997). Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J. Neuropathol. Exp. Neurol. 56, 440-454. doi: 10.1097/00005072-199704000-00013
8. Ayala-Peña, S. (2013). Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis. Free Radic. Biol. Med. 62, 102-110. doi: 10.1016/j.freeradbiomed.2013.04.017
9. Azbill, R. D., Mu, X., and Springer, J. E. (2000). Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res. 871, 175-180. doi: 10.1016/S0006-8993(00)02430-6
10. Baker, D. A., McFarland, K., Lake, R. W., Shen, H., Tang, X. C., Toda, S., et al. (2003). Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat. Neurosci. 6, 743-749. doi: 10.1038/nn1069
11. Baker, D. A., Xi, Z. X., Shen, H., Swanson, C. J., and Kalivas, P. W. (2002). The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci. 22, 9134-9141.
12. Bannai, S., and Ishii, T. (1982). Transport of cystine and cysteine and cell growth in cultured human diploid fibroblasts: effect of glutamate and homocysteate. J. Cell. Physiol. 112, 265-272. doi: 10.1002/jcp.1041120216
13. Bao, X., Pal, R., Hascup, K. N., Wang, Y., Wang, W. T., Xu, W., et al. (2009). Transgenic expression of Glud1 (glutamate dehydrogenase 1) in neurons: in vivo model of enhanced glutamate release, altered synaptic plasticity, and selective neuronal vulnerability. J. Neurosci. 29, 13929-13944. doi: 10.1523/JNEUROSCI.4413-09.2009
14. Baran, H., Jellinger, K., and Deecke, L. (1999). Kynurenine metabolism in Alzheimer's disease. J. Neural Transm. 106, 165-181. doi: 10.1007/s007020050149
15. Baran, H., and Schwarcz, R. (1990). Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain. J. Neurochem. 55, 738-744. doi: 10.1111/j.1471-4159.1990.tb04553.x
16. Basun, H., Forssell, L. G., Almkvist, O., Cowburn, R. F., Eklöf, R., Winblad, B., et al. (1990). Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer's disease and healthy control subjects. J. Neural Transm. Park. Dis. Dement. Sect. 2, 295-304. doi: 10.1007/BF02252924
17. Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., and Martin, J. B. (1986). Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171. doi: 10.1038/321168a0
18. Beal, M. F., Matson, W. R., Storey, E., Milbury, P., Ryan, E. A., Ogawa, T., et al. (1992). Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 108, 80-87. doi: 10.1016/0022-510X(92)90191-M
19. Beckstrøm, H., Julsrud, L., Haugeto, O., Dewar, D., Graham, D. I., Lehre, K. P., et al. (1999). Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. J. Neurosci. Res. 55, 218-229.
20. Behrens, P. F., Franz, P., Woodman, B., Lindenberg, K. S., and Landwehrmeyer, G. B. (2002). Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125, 1908-1922. doi: 10.1093/brain/awf180
21. Bendotti, C., Tortarolo, M., Suchak, S. K., Calvaresi, N., Carvelli, L., Bastone, A., et al. (2001). Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J. Neurochem. 79, 737-746. doi: 10.1046/j.1471-4159.2001.00572.x
22. Berdichevsky, E., Riveros, N., Sánchez-Armáss, S., and Orrego, F. (1983). Kainate, N-methylaspartate and other excitatory amino acids increase calcium influx into rat brain cortex cells in vitro. Neurosci. Lett. 36, 75-80. doi: 10.1016/0304-3940(83)90489-5
23. Berlinguer-Palmini, R., Masi, A., Narducci, R., Cavone, L., Maratea, D., Cozzi, A., et al. (2013). GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses. PLoS ONE 8:e82180. doi: 10.1371/journal.pone.0082180
24. Bielenberg, G. W., and Beck, T. (1991). The effects of dizocilpine (MK-801), phencyclidine, and nimodipine on infarct size 48 h after middle cerebral artery occlusion in the rat. Brain Res. 552, 338-342. doi: 10.1016/0006-8993(91)90101-Z
25. Birley, S., Collins, J. F., Perkins, M. N., and Stone, T. W. (1982). The effects of cyclic dicarboxylic acids on spontaneous and amino acid-evoked activity of rat cortical neurones. Br. J. Pharmacol. 77, 7-12. doi: 10.1111/j.1476-5381.1982.tb09262.x
26. Bogdanov, M. B., Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., and Beal, M. F. (2001). Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79, 1246-1249. doi: 10.1046/j.1471-4159.2001.00689.x
27. Brunet, N., Tarabal, O., Esquerda, J. E., and Calderó, J. (2009). Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord. J. Comp. Neurol. 516, 277-290. doi: 10.1002/cne.22118
28. Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri, M., et al. (2001). Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 13, 2141-2147. doi: 10.1046/j.0953-816x.2001.01592.x
29. Carriedo, S. G., Yin, H. Z., and Weiss, J. H. (1996). Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. 16, 4069-4079.
30. Chaudhry, F. A., Lehre, K. P., van Lookeren Campagne, M., Ottersen, O. P., Danbolt, N. C., and Storm-Mathisen, J. (1995). Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 15, 711-720. doi: 10.1016/0896-6273(95)90158-2
31. Chen, N., Luo, T., Wellington, C., Metzler, M., McCutcheon, K., Hayden, M. R., et al. (1999). Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 72, 1890-1898. doi: 10.1046/j.1471-4159.1999.0721890.x
32. Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., et al. (2010). The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox. Res. 18, 132-142. doi: 10.1007/s12640-009-9129-7
33. Choi, D. W. (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634. doi: 10.1016/0896-6273(88)90162-6
34. Choi, D. W. (1992). Excitotoxic cell death. J. Neurobiol. 23, 1261-1276. doi: 10.1002/neu.480230915
35. Colton, C. K., Kong, Q., Lai, L., Zhu, M. X., Seyb, K. I., Cuny, G. D., et al. (2010). Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J. Biomol. Screen. 15, 653-662. doi: 10.1177/1087057110370998
36. Coulter, D. A., and Eid, T. (2012). Astrocytic regulation of glutamate homeostasis in epilepsy. Glia 60, 1215-1226. doi: 10.1002/glia.22341
37. Coyle, J. T., and Schwarcz, R. (1976). Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263, 244-246. doi: 10.1038/263244a0
38. Csernansky, J. G., Bardgett, M. E., Sheline, Y. I., Morris, J. C., and Olney, J. W. (1996). CSF excitatory amino acids and severity of illness in Alzheimer's disease. Neurology 46, 1715-1720. doi: 10.1212/WNL.46.6.1715
39. Curtis, D. R., Phillis, J. W., and Watkins, J. C. (1960). The chemical excitation of spinal neurones by certain acidic amino acids. J. Physiol. (Lond). 150, 656-682. doi: 10.1113/jphysiol.1960.sp006410
40. de Belleroche, J., Recordati, A., and Rose, F. C. (1984). Elevated levels of amino acids in the CSF of motor neuron disease patients. Neurochem. Pathol. 2, 1-6. doi: 10.1007/BF02834167
41. Debono, M. W., Le Guern, J., Canton, T., Doble, A., and Pradier, L. (1993). Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 235, 283-289. doi: 10.1016/0014-2999(93)90147-A
42. De Bundel, D., Schallier, A., Loyens, E., Fernando, R., Miyashita, H., Van Liefferinge, J., et al. (2011). Loss of system x(c)-formula does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J. Neurosci. 31, 5792-5803. doi: 10.1523/JNEUROSCI.5465-10.2011
43. Deng, Y., Xiong, Z., Chen, P., Wei, J., Chen, S., and Yan, Z. (2014). beta-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3. Neurobiol. Aging 35, 449-459. doi: 10.1016/j.neurobiolaging.2013.08.031
44. Dirnagl, U., Iadecola, C., and Moskowitz, M. A. (1999). Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391-397. doi: 10.1016/S0166-2236(99)01401-0
45. Do, K. Q., Herrling, P. L., Streit, P., Turski, W. A., and Cuenod, M. (1986). In vitro release and electrophysiological effects in situ of homocysteic acid, an endogenous N-methyl-(D)-aspartic acid agonist, in the mammalian striatum. J. Neurosci. 6, 2226-2234.
46. Dzubay, J. A., and Jahr, C. E. (1999). The concentration of synaptically released glutamate outside of the climbing fiber-Purkinje cell synaptic cleft. J. Neurosci. 19, 5265-5274.
47. Emnett, C. M., Eisenman, L. N., Taylor, A. M., Izumi, Y., Zorumski, C. F., and Mennerick, S. (2013). Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Mol. Pharmacol. 84, 935-947. doi: 10.1124/mol.113.089334
48. Estrada-Sánchez, A. M., Montiel, T., Segovia, J., and Massieu, L. (2009). Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol. Dis. 34, 78-86. doi: 10.1016/j.nbd.2008.12.017
49. Fan, J., Cowan, C. M., Zhang, L. Y., Hayden, M. R., and Raymond, L. A. (2009). Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J. Neurosci. 29, 10928-10938. doi: 10.1523/JNEUROSCI.2491-09.2009
50. Fan, J., Gladding, C. M., Wang, L., Zhang, L. Y., Kaufman, A. M., Milnerwood, A. J., et al. (2012). P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 45, 999-1009. doi: 10.1016/j.nbd.2011.12.019
51. Fogal, B., Li, J., Lobner, D., McCullough, L. D., and Hewett, S. J. (2007). System x(c)-activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. J. Neurosci. 27, 10094-10105. doi: 10.1523/JNEUROSCI.2459-07.2007
52. Fonnum, F. (1984). Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42, 1-11. doi: 10.1111/j.1471-4159.1984.tb09689.x
53. Fontana, A. C., Fox, D. P., Zoubroulis, A., Mortensen, O. V., and Raghupathi, R. (2015). Neuroprotective effects of the glutamate transporter activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153), following traumatic brain injury in the adult rat. J. Neurotrauma. doi: 10.1089/neu.2015.4079. [Epub ahead of print].
54. Foster, A. C., Vezzani, A., French, E. D., and Schwarcz, R. (1984). Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48, 273-278. doi: 10.1016/0304-3940(84)90050-8
55. Frauscher, G., Karnaukhova, E., Muehl, A., Hoeger, H., and Lubec, B. (1995). Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid-additional mechanisms in homocysteine induced endothelial damage? Life Sci. 57, 813-817. doi: 10.1016/0024-3205(95)02009-8
56. Frederick, N. M., Bertho, J., Patel, K. K., Petr, G. T., Bakradze, E., Smith, S. B., et al. (2014). Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice. Neurochem. Int. 76, 59-69. doi: 10.1016/j.neuint.2014.06.017
57. Freire, M. A. (2012). Pathophysiology of neurodegeneration following traumatic brain injury. West Indian Med. J. 61, 751-755.
58. Fuchs, A., Kutterer, S., Mühling, T., Duda, J., Schütz, B., Liss, B., et al. (2013). Selective mitochondrial Ca2+ uptake deficit in disease endstage vulnerable motoneurons of the SOD1G93A mouse model of amyotrophic lateral sclerosis. J. Physiol. (Lond). 591, 2723-2745. doi: 10.1113/jphysiol.2012.247981
59. Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., and Smith, Q. R. (1991). Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56, 2007-2017. doi: 10.1111/j.1471-4159.1991.tb03460.x
60. Gál, E. M., and Sherman, A. D. (1978). Synthesis and metabolism of L-kynurenine in rat brain. J. Neurochem. 30, 607-613. doi: 10.1111/j.1471-4159.1978.tb07815.x
61. Ganel, R., Ho, T., Maragakis, N. J., Jackson, M., Steiner, J. P., and Rothstein, J. D. (2006). Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol. Dis. 21, 556-567. doi: 10.1016/j.nbd.2005.08.014
62. Ganong, A. H., and Cotman, C. W. (1986). Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. J. Pharmacol. Exp. Ther. 236, 293-299.
63. Ganong, A. H., Lanthorn, T. H., and Cotman, C. W. (1983). Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. Brain Res. 273, 170-174. doi: 10.1016/0006-8993(83)91108-3
64. Gianfriddo, M., Melani, A., Turchi, D., Giovannini, M. G., and Pedata, F. (2004). Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol. Dis. 17, 77-88. doi: 10.1016/j.nbd.2004.05.008
65. Graham, S. H., Shiraishi, K., Panter, S. S., Simon, R. P., and Faden, A. I. (1990). Changes in extracellular amino acid neurotransmitters produced by focal cerebral ischemia. Neurosci. Lett. 110, 124-130. doi: 10.1016/0304-3940(90)90799-F
66. Grant, K. S., Burbacher, T. M., Faustman, E. M., and Gratttan, L. (2010). Domoic acid: neurobehavioral consequences of exposure to a prevalent marine biotoxin. Neurotoxicol. Teratol. 32, 132-141. doi: 10.1016/j.ntt.2009.09.005
67. Grilli, M., Diodato, E., Lozza, G., Brusa, R., Casarini, M., Uberti, D., et al. (2000). Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc. Natl. Acad. Sci. U.S.A. 97, 12822-12827. doi: 10.1073/pnas.97.23.12822
68. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 83, 4913-4917. doi: 10.1073/pnas.83.13.4913
69. Guidetti, P., Bates, G. P., Graham, R. K., Hayden, M. R., Leavitt, B. R., MacDonald, M. E., et al. (2006). Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 23, 190-197. doi: 10.1016/j.nbd.2006.02.011
70. Guidetti, P., Luthi-Carter, R. E., Augood, S. J., and Schwarcz, R. (2004). Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455-461. doi: 10.1016/j.nbd.2004.07.006
71. Guidetti, P., and Schwarcz, R. (1999). 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11, 3857-3863. doi: 10.1046/j.1460-9568.1999.00806.x
72. Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., and Cullen, K. M. (2005). Indoleamine 2, 3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 31, 395-404. doi: 10.1111/j.1365-2990.2005.00655.x
73. Guillemin, G. J., Smythe, G. A., Veas, L. A., Takikawa, O., and Brew, B. J. (2003). A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 14, 2311-2315. doi: 10.1097/00001756-200312190-00005
74. Gundersen, V., Chaudhry, F. A., Bjaalie, J. G., Fonnum, F., Ottersen, O. P., and Storm-Mathisen, J. (1998). Synaptic vesicular localization and exocytosis of L-aspartate in excitatory nerve terminals: a quantitative immunogold analysis in rat hippocampus. J. Neurosci. 18, 6059-6070.
75. Gundersen, V., Ottersen, O. P., and Storm-Mathisen, J. (1991). Aspartate-and glutamate-like immunoreactivities in rat hippocampal slices: depolarization-induced redistribution and effects of precursors. Eur. J. Neurosci. 3, 1281-1299. doi: 10.1111/j.1460-9568.1991.tb00061.x
76. Guo, H., Lai, L., Butchbach, M. E., Stockinger, M. P., Shan, X., Bishop, G. A., et al. (2003). Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. 12, 2519-2532. doi: 10.1093/hmg/ddg267
77. Ha, J. S., Lee, C. S., Maeng, J. S., Kwon, K. S., and Park, S. S. (2009). Chronic glutamate toxicity in mouse cortical neuron culture. Brain Res. 1273, 138-143. doi: 10.1016/j.brainres.2009.03.050
78. Hansson, O., Castilho, R. F., Korhonen, L., Lindholm, D., Bates, G. P., and Brundin, P. (2001a). Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J. Neurochem. 78, 694-703. doi: 10.1046/j.1471-4159.2001.00482.x
79. Hansson, O., Guatteo, E., Mercuri, N. B., Bernardi, G., Li, X. J., Castilho, R. F., et al. (2001b). Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 14, 1492-1504. doi: 10.1046/j.0953-816x.2001.01767.x
80. Hansson, O., Petersén, A., Leist, M., Nicotera, P., Castilho, R. F., and Brundin, P. (1999). Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. U.S.A. 96, 8727-8732. doi: 10.1073/pnas.96.15.8727
81. Hardingham, G. E., Arnold, F. J., and Bading, H. (2001). Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat. Neurosci. 4, 261-267. doi: 10.1038/85109
82. Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405-414. doi: 10.1038/nn835
83. Harris, A. Z., and Pettit, D. L. (2007). Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J. Physiol. (Lond). 584, 509-519. doi: 10.1113/jphysiol.2007.137679
84. Hashimoto, A., Kumashiro, S., Nishikawa, T., Oka, T., Takahashi, K., Mito, T., et al. (1993). Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex. J. Neurochem. 61, 348-351. doi: 10.1111/j.1471-4159.1993.tb03575.x
85. Hashimoto, A., Nishikawa, T., Hayashi, T., Fujii, N., Harada, K., Oka, T., et al. (1992). The presence of free D-serine in rat brain. FEBS Lett. 296, 33-36. doi: 10.1016/0014-5793(92)80397-Y
86. Hayes, D., Wiessner, M., Rauen, T., and McBean, G. J. (2005). Transport of L-[14C]cystine and L-[14C]cysteine by subtypes of high affinity glutamate transporters over-expressed in HEK cells. Neurochem. Int. 46, 585-594. doi: 10.1016/j.neuint.2005.03.001
87. Henneberger, C., Papouin, T., Oliet, S. H., and Rusakov, D. A. (2010). Long-term potentiation depends on release of D-serine from astrocytes. Nature 463, 232-236. doi: 10.1038/nature08673
88. Hertz, L. (2006). Glutamate, a neurotransmitter-and so much more. A synopsis of Wierzba III. Neurochem. Int. 48, 416-425. doi: 10.1016/j.neuint.2005.12.021
89. Holopainen, I., and Kontro, P. (1989). Uptake and release of glycine in cerebellar granule cells and astrocytes in primary culture: potassium-stimulated release from granule cells is calcium-dependent. J. Neurosci. Res. 24, 374-383. doi: 10.1002/jnr.490240306
90. Howland, D. S., Liu, J., She, Y., Goad, B., Maragakis, N. J., Kim, B., et al. (2002). Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U.S.A. 99, 1604-1609. doi: 10.1073/pnas.032539299
91. Huang, K., Kang, M. H., Askew, C., Kang, R., Sanders, S. S., Wan, J., et al. (2010). Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 40, 207-215. doi: 10.1016/j.nbd.2010.05.027
92. Ikonomidou, C., Qin Qin, Y., Labruyere, J., and Olney, J. W. (1996). Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 55, 211-224. doi: 10.1097/00005072-199602000-00010
93. Ilzecka, J., Kocki, T., Stelmasiak, Z., and Turski, W. A. (2003). Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol. Scand. 107, 412-418. doi: 10.1034/j.1600-0404.2003.00076.x
94. Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E. T., Frosch, M. P., et al. (2004). Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925-931. doi: 10.1212/01.WNL.0000115115.98960.37
95. Ito, S., and Cherubini, E. (1991). Strychnine-sensitive glycine responses of neonatal rat hippocampal neurones. J. Physiol. (Lond). 440, 67-83. doi: 10.1113/jphysiol.1991.sp018696
96. Jarabek, B. R., Yasuda, R. P., and Wolfe, B. B. (2004). Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127, 505-516. doi: 10.1093/brain/awh058
97. Jimenez-Jimenez, F. J., Molina, J. A., Gomez, P., Vargas, C., de Bustos, F., Benito-Leon, J., et al. (1998). Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J. Neural Transm. 105, 269-277. doi: 10.1007/s007020050073
98. Johnson, J. W., and Ascher, P. (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325, 529-531. doi: 10.1038/325529a0
99. Johri, A., and Beal, M. F. (2012). Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 342, 619-630. doi: 10.1124/jpet.112.192138
100. Johri, A., Chandra, A., and Beal, M. F. (2013). PGC-1alpha, mitochondrial dysfunction, and Huntington's disease. Free Radic. Biol. Med. 62, 37-46. doi: 10.1016/j.freeradbiomed.2013.04.016
101. Kaiser, E., Schoenknecht, P., Kassner, S., Hildebrandt, W., Kinscherf, R., and Schroeder, J. (2010). Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease. Neurodegener. Dis. 7, 251-259. doi: 10.1159/000287953
102. Kalbaugh, T. L., Zhang, J., and Diamond, J. S. (2009). Coagonist release modulates NMDA receptor subtype contributions at synaptic inputs to retinal ganglion cells. J. Neurosci. 29, 1469-1479. doi: 10.1523/JNEUROSCI.4240-08.2009
103. Karamyan, V. T., and Speth, R. C. (2008). Animal models of BMAA neurotoxicity: a critical review. Life Sci. 82, 233-246. doi: 10.1016/j.lfs.2007.11.020
104. Katsuta, K., Nakanishi, H., Shirakawa, K., Yoshida, K., Takagi, K., and Tamura, A. (1995). The neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427 in focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 15, 345-348. doi: 10.1038/jcbfm.1995.40
105. Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007). Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116. doi: 10.1146/annurev.pharmtox.46.120604.141046
106. Kilpatrick, I. C., and Mozley, L. S. (1986). An initial analysis of the regional distribution of excitatory sulphur-containing amino acids in the rat brain. Neurosci. Lett. 72, 189-193. doi: 10.1016/0304-3940(86)90078-9
107. Kim, K., Lee, S. G., Kegelman, T. P., Su, Z. Z., Das, S. K., Dash, R., et al. (2011). Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J. Cell. Physiol. 226, 2484-2493. doi: 10.1002/jcp.22609
108. Kiryk, A., Aida, T., Tanaka, K., Banerjee, P., Wilczynski, G. M., Meyza, K., et al. (2008). Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction. Neurotox. Res. 13, 19-30. doi: 10.1007/BF03033364
109. Kleckner, N. W., and Dingledine, R. (1988). Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241, 835-837. doi: 10.1126/science.2841759
110. Knackstedt, L. A., Melendez, R. I., and Kalivas, P. W. (2010). Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol. Psychiatry 67, 81-84. doi: 10.1016/j.biopsych.2009.07.018
111. Kong, Q., Chang, L. C., Takahashi, K., Liu, Q., Schulte, D. A., Lai, L., et al. (2014). Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J. Clin. Invest. 124, 1255-1267. doi: 10.1172/JCI66163
112. Kuiper, M. A., Teerlink, T., Visser, J. J., Bergmans, P. L., Scheltens, P., and Wolters, E. C. (2000). L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 107, 183-189. doi: 10.1007/s007020050016
113. Landwehrmeyer, G. B., Standaert, D. G., Testa, C. M., Penney, J. B. Jr., and Young, A. B. (1995). NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 15, 5297-5307.
114. Leal, S. S., and Gomes, C. M. (2015). Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability. Front. Cell. Neurosci. 9:225. doi: 10.3389/fncel.2015.00225
115. Le Bail, M., Martineau, M., Sacchi, S., Yatsenko, N., Radzishevsky, I., Conrod, S., et al. (2015). Identity of the NMDA receptor coagonist is synapse specific and developmentally regulated in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 112, E204-E213. doi: 10.1073/pnas.1416668112
116. Lefauconnier, J. M., Portemer, C., and Chatagner, F. (1976). Free amino acids and related substances in human glial tumours and in fetal brain: comparison with normal adult brain. Brain Res. 117, 105-113. doi: 10.1016/0006-8993(76)90559-X
117. Levine, M. S., Klapstein, G. J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M. E., et al. (1999). Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58, 515-532.
118. Lewerenz, J., Albrecht, P., Tien, M. L., Henke, N., Karumbayaram, S., Kornblum, H. I., et al. (2009). Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 111, 332-343. doi: 10.1111/j.1471-4159.2009.06347.x
119. Li, S., Mallory, M., Alford, M., Tanaka, S., and Masliah, E. (1997). Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56, 901-911. doi: 10.1097/00005072-199708000-00008
120. Liévens, J. C., Woodman, B., Mahal, A., Spasic-Boscovic, O., Samuel, D., Kerkerian-Le Goff, L., et al. (2001). Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 8, 807-821. doi: 10.1006/nbdi.2001.0430
121. Lin, C. L., Bristol, L. A., Jin, L., Dykes-Hoberg, M., Crawford, T., Clawson, L., et al. (1998). Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20, 589-602. doi: 10.1016/S0896-6273(00)80997-6
122. Liu, X., Rush, T., Zapata, J., and Lobner, D. (2009). beta-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system Xc(-). Exp. Neurol. 217, 429-433. doi: 10.1016/j.expneurol.2009.04.002
123. Lobner, D., Piana, P. M., Salous, A. K., and Peoples, R. W. (2007). Beta-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol. Dis. 25, 360-366. doi: 10.1016/j.nbd.2006.10.002
124. Lodge, D. (2009). The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology 56, 6-21. doi: 10.1016/j.neuropharm.2008.08.006
125. Loss, C. M., Córdova, S. D., and de Oliveira, D. L. (2012). Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. Brain Res. 1474, 110-117. doi: 10.1016/j.brainres.2012.07.046
126. Ludolph, A. C., and Spencer, P. S. (1995). Toxic neuropathies and their treatment. Baillieres. Clin. Neurol. 4, 505-527.
127. Luján, R., Roberts, J. D., Shigemoto, R., Ohishi, H., and Somogyi, P. (1997). Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites. J. Chem. Neuroanat. 13, 219-241. doi: 10.1016/S0891-0618(97)00051-3
128. Majd, S., Power, J. H., and Grantham, H. J. (2015). Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways. BMC Neurosci. 16:69. doi: 10.1186/s12868-015-0211-1
129. Marmiroli, P., and Cavaletti, G. (2012). The glutamatergic neurotransmission in the central nervous system. Curr. Med. Chem. 19, 1269-1276. doi: 10.2174/092986712799462711
130. Martinez, M., Frank, A., Diez-Tejedor, E., and Hernanz, A. (1993). Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J. Neural Transm. Park. Dis. Dement. Sect. 6, 1-9. doi: 10.1007/BF02252617
131. Massie, A., Boillée, S., Hewett, S., Knackstedt, L., and Lewerenz, J. (2015). Main path and byways: non-vesicular glutamate release by system x-c as an important modifier of glutamatergic neurotransmission. J. Neurochem. [Epub ahead of print]. doi: 10.1111/jnc.13348
132. Massie, A., Schallier, A., Kim, S. W., Fernando, R., Kobayashi, S., Beck, H., et al. (2011). Dopaminergic neurons of system x(c)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. FASEB J. 25, 1359-1369. doi: 10.1096/fj.10-177212
133. Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R. E. (1992). beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376-389.
134. Mazarei, G., Budac, D. P., Lu, G., Adomat, H., Tomlinson Guns, E. S., Möller, T., et al. (2013a). Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J. Neurochem. 127, 852-867. doi: 10.1111/jnc.12350
135. Mazarei, G., Budac, D. P., Lu, G., Lee, H., Möller, T., and Leavitt, B. R. (2013b). The absence of indoleamine 2, 3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Exp. Neurol. 249, 144-148. doi: 10.1016/j.expneurol.2013.08.007
136. McBean, G. J. (2012). The transsulfuration pathway: a source of cysteine for glutathione in astrocytes. Amino Acids 42, 199-205. doi: 10.1007/s00726-011-0864-8
137. Meldrum, B., and Garthwaite, J. (1990). Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11, 379-387. doi: 10.1016/0165-6147(90)90184-A
138. Meldrum, B. S. (1994). The role of glutamate in epilepsy and other CNS disorders. Neurology 44, S14-23.
139. Melendez, R. I., Vuthiganon, J., and Kalivas, P. W. (2005). Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 314, 139-147. doi: 10.1124/jpet.104.081521
140. Mesci, P., Zaïdi, S., Lobsiger, C. S., Millecamps, S., Escartin, C., Seilhean, D., et al. (2015). System xC-is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain 138, 53-68. doi: 10.1093/brain/awu312
141. Millecamps, S., Da Barroca, S., Cazeneuve, C., Salachas, F., Pradat, P. F., Danel-Brunaud, V., et al. (2010). Questioning on the role of D amino acid oxidase in familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 107, E107; author reply E108. doi: 10.1073/pnas.1006190107
142. Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., et al. (2008). Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153, 329-337. doi: 10.1016/j.neuroscience.2008.02.004
143. Miller, R. G., Mitchell, J. D., and Moore, D. H. (2012). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 3:CD001447. doi: 10.1002/14651858.CD001447.pub3
144. Milnerwood, A. J., Gladding, C. M., Pouladi, M. A., Kaufman, A. M., Hines, R. M., Boyd, J. D., et al. (2010). Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65, 178-190. doi: 10.1016/j.neuron.2010.01.008
145. Mitani, A., and Tanaka, K. (2003). Functional changes of glial glutamate transporter GLT-1 during ischemia: an in vivo study in the hippocampal CA1 of normal mice and mutant mice lacking GLT-1. J. Neurosci. 23, 7176-7182.
146. Mitchell, J., Paul, P., Chen, H. J., Morris, A., Payling, M., Falchi, M., et al. (2010). Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc. Natl. Acad. Sci. U.S.A. 107, 7556-7561. doi: 10.1073/pnas.0914128107
147. Miyamoto, E. (2006). Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J. Pharmacol. Sci. 100, 433-442. doi: 10.1254/jphs.CPJ06007X
148. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., and Seeburg, P. H. (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12, 529-540. doi: 10.1016/0896-6273(94)90210-0
149. Mookherjee, P., Green, P. S., Watson, G. S., Marques, M. A., Tanaka, K., Meeker, K. D., et al. (2011). GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model. J. Alzheimers. Dis. 26, 447-455. doi: 10.3233/JAD-2011-110503
150. Morel, L., Regan, M., Higashimori, H., Ng, S. K., Esau, C., Vidensky, S., et al. (2013). Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. J. Biol. Chem. 288, 7105-7116. doi: 10.1074/jbc.M112.410944
151. Moroni, F., Russi, P., Carlá, V., and Lombardi, G. (1988). Kynurenic acid is present in the rat brain and its content increases during development and aging processes. Neurosci. Lett. 94, 145-150. doi: 10.1016/0304-3940(88)90285-6
152. Mothet, J. P., Pollegioni, L., Ouanounou, G., Martineau, M., Fossier, P., and Baux, G. (2005). Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine. Proc. Natl. Acad. Sci. U.S.A. 102, 5606-5611. doi: 10.1073/pnas.0408483102
153. Nance, M. A. (1997). Clinical aspects of CAG repeat diseases. Brain Pathol. 7, 881-900. doi: 10.1111/j.1750-3639.1997.tb00892.x
154. Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., et al. (2015). Oxidative stress in neurodegenerative diseases. Mol. Neurobiol. 1-32. doi: 10.1007/s12035-015-9337-5
155. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. doi: 10.1016/S0896-6273(03)00434-3
156. Olney, J. W. (1986). Inciting excitotoxic cytocide among central neurons. Adv. Exp. Med. Biol. 203, 631-645. doi: 10.1007/978-1-4684-7971-3_48
157. Overk, C. R., and Masliah, E. (2014). Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem. Pharmacol. 88, 508-516. doi: 10.1016/j.bcp.2014.01.015
158. Palaiologos, G., Hertz, L., and Schousboe, A. (1988). Evidence that aspartate aminotransferase activity and ketodicarboxylate carrier function are essential for biosynthesis of transmitter glutamate. J. Neurochem. 51, 317-320. doi: 10.1111/j.1471-4159.1988.tb04872.x
159. Paleacu, D., Cohn, D. F., and Rabey, J. M. (1999). Cognitive evaluation of patients with chronic neurolathyrism. Parkinsonism Relat. Disord. 5, 55-58. doi: 10.1016/S1353-8020(99)00016-4
160. Paoletti, P., and Neyton, J. (2007). NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7, 39-47. doi: 10.1016/j.coph.2006.08.011
161. Papouin, T., Ladépêche, L., Ruel, J., Sacchi, S., Labasque, M., Hanini, M., et al. (2012). Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150, 633-646. doi: 10.1016/j.cell.2012.06.029
162. Papouin, T., and Oliet, S. H. (2014). Organization, control and function of extrasynaptic NMDA receptors. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369:20130601. doi: 10.1098/rstb.2013.0601
163. Pardo, A. C., Wong, V., Benson, L. M., Dykes, M., Tanaka, K., Rothstein, J. D., et al. (2006). Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice. Exp. Neurol. 201, 120-130. doi: 10.1016/j.expneurol.2006.03.028
164. Park, C. K., Nehls, D. G., Graham, D. I., Teasdale, G. M., and McCulloch, J. (1988). The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol. 24, 543-551. doi: 10.1002/ana.410240411
165. Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J. Y., et al. (2005). Astrocytic purinergic signaling coordinates synaptic networks. Science 310, 113-116. doi: 10.1126/science.1116916
166. Patel, S. A., Warren, B. A., Rhoderick, J. F., and Bridges, R. J. (2004). Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 46, 273-284. doi: 10.1016/j.neuropharm.2003.08.006
167. Patneau, D. K., and Mayer, M. L. (1990). Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors. J. Neurosci. 10, 2385-2399.
168. Perry, T. L., Hansen, S., Berry, K., Mok, C., and Lesk, D. (1971). Free amino acids and related compounds in biopsies of human brain. J. Neurochem. 18, 521-528. doi: 10.1111/j.1471-4159.1971.tb11980.x
169. Perry, T. L., Krieger, C., Hansen, S., and Eisen, A. (1990). Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann. Neurol. 28, 12-17. doi: 10.1002/ana.410280105
170. Petersén, A., Hansson, O., Puschban, Z., Sapp, E., Romero, N., Castilho, R. F., et al. (2001). Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur. J. Neurosci. 14, 1425-1435. doi: 10.1046/j.0953-816x.2001.01765.x
171. Petr, G. T., Schultheis, L. A., Hussey, K. C., Sun, Y., Dubinsky, J. M., Aoki, C., et al. (2013). Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression. Eur. J. Neurosci. 38, 2477-2490. doi: 10.1111/ejn.12202
172. Petr, G. T., Sun, Y., Frederick, N. M., Zhou, Y., Dhamne, S. C., Hameed, M. Q., et al. (2015). Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J. Neurosci. 35, 5187-5201. doi: 10.1523/JNEUROSCI.4255-14.2015
173. Petralia, R. S., Wang, Y. X., Hua, F., Yi, Z., Zhou, A., Ge, L., et al. (2010). Organization of NMDA receptors at extrasynaptic locations. Neuroscience 167, 68-87. doi: 10.1016/j.neuroscience.2010.01.022
174. Pomara, N., Singh, R., Deptula, D., Chou, J. C., Schwartz, M. B., and LeWitt, P. A. (1992). Glutamate and other CSF amino acids in Alzheimer's disease. Am. J. Psychiatry 149, 251-254. doi: 10.1176/ajp.149.2.251
175. Pullan, L. M., Olney, J. W., Price, M. T., Compton, R. P., Hood, W. F., Michel, J., et al. (1987). Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids. J. Neurochem. 49, 1301-1307. doi: 10.1111/j.1471-4159.1987.tb10024.x
176. Qin, S., Colin, C., Hinners, I., Gervais, A., Cheret, C., and Mallat, M. (2006). System Xc-and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J. Neurosci. 26, 3345-3356. doi: 10.1523/JNEUROSCI.5186-05.2006
177. Qiu, S., Pak, C. W., and Currás-Collazo, M. C. (2006). Sequential involvement of distinct glutamate receptors in domoic acid-induced neurotoxicity in rat mixed cortical cultures: effect of multiple dose/duration paradigms, chronological age, and repeated exposure. Toxicol. Sci. 89, 243-256. doi: 10.1093/toxsci/kfj008
178. Quinn, C. T., Griener, J. C., Bottiglieri, T., Hyland, K., Farrow, A., and Kamen, B. A. (1997). Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J. Clin. Oncol. 15, 2800-2806.
179. Radi, E., Formichi, P., Battisti, C., and Federico, A. (2014). Apoptosis and oxidative stress in neurodegenerative diseases. J. Alzheimers. Dis. 42(Suppl. 3), S125-S152. doi: 10.3233/JAD-132738
180. Ringman, J. M., Goate, A., Masters, C. L., Cairns, N. J., Danek, A., Graff-Radford, N., et al. (2014). Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr. Neurol. Neurosci. Rep. 14:499. doi: 10.1007/s11910-014-0499-8
181. Rosenberg, D., Artoul, S., Segal, A. C., Kolodney, G., Radzishevsky, I., Dikopoltsev, E., et al. (2013). Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity. J. Neurosci. 33, 3533-3544. doi: 10.1523/JNEUROSCI.3836-12.2013
182. Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., et al. (1996). Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686. doi: 10.1016/S0896-6273(00)80086-0
183. Rothstein, J. D., Jin, L., Dykes-Hoberg, M., and Kuncl, R. W. (1993). Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 90, 6591-6595. doi: 10.1073/pnas.90.14.6591
184. Rothstein, J. D., Martin, L. J., and Kuncl, R. W. (1992). Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326, 1464-1468. doi: 10.1056/NEJM199205283262204
185. Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., et al. (2005). Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77. doi: 10.1038/nature03180
186. Rothstein, J. D., Tsai, G., Kuncl, R. W., Clawson, L., Cornblath, D. R., Drachman, D. B., et al. (1990). Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 28, 18-25. doi: 10.1002/ana.410280106
187. Sagara, Y., and Schubert, D. (1998). The activation of metabotropic glutamate receptors protects nerve cells from oxidative stress. J. Neurosci. 18, 6662-6671.
188. Sankar, R., Shin, D. H., Liu, H., Mazarati, A., Pereira de Vasconcelos, A., and Wasterlain, C. G. (1998). Patterns of status epilepticus-induced neuronal injury during development and long-term consequences. J. Neurosci. 18, 8382-8393.
189. Sasabe, J., Chiba, T., Yamada, M., Okamoto, K., Nishimoto, I., Matsuoka, M., et al. (2007). D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J. 26, 4149-4159. doi: 10.1038/sj.emboj.7601840
190. Sasabe, J., Miyoshi, Y., Suzuki, M., Mita, M., Konno, R., Matsuoka, M., et al. (2012). D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc. Natl. Acad. Sci. U.S.A. 109, 627-632. doi: 10.1073/pnas.1114639109
191. Sasaki, S., Komori, T., and Iwata, M. (2000). Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol. 100, 138-144. doi: 10.1007/s004019900159
192. Sato, H., Tamba, M., Ishii, T., and Bannai, S. (1999). Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 274, 11455-11458. doi: 10.1074/jbc.274.17.11455
193. Schallier, A., Smolders, I., Van Dam, D., Loyens, E., De Deyn, P. P., Michotte, A., et al. (2011). Region-and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer's disease. J. Alzheimers. Dis. 24, 287-300. doi: 10.3233/JAD-2011-101005
194. Schell, M. J., Molliver, M. E., and Snyder, S. H. (1995). D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. U.S.A. 92, 3948-3952. doi: 10.1073/pnas.92.9.3948
195. Schubert, D., and Piasecki, D. (2001). Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J. Neurosci. 21, 7455-7462.
196. Schwarcz, R., and Pellicciari, R. (2002). Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 303, 1-10. doi: 10.1124/jpet.102.034439
197. Schwarcz, R., Whetsell, W. O. Jr., and Mangano, R. M. (1983). Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316-318. doi: 10.1126/science.6849138
198. Scimemi, A., Meabon, J. S., Woltjer, R. L., Sullivan, J. M., Diamond, J. S., and Cook, D. G. (2013). Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J. Neurosci. 33, 5312-5318. doi: 10.1523/JNEUROSCI.5274-12.2013
199. Scott, H. A., Gebhardt, F. M., Mitrovic, A. D., Vandenberg, R. J., and Dodd, P. R. (2011). Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol. Aging 32, 553.e1-553.e11. doi: 10.1016/j.neurobiolaging.2010.03.008
200. Shehadeh, J., Fernandes, H. B., Zeron Mullins, M. M., Graham, R. K., Leavitt, B. R., Hayden, M. R., et al. (2006). Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 21, 392-403. doi: 10.1016/j.nbd.2005.08.001
201. Sheldon, A. L., and Robinson, M. B. (2007). The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem. Int. 51, 333-355. doi: 10.1016/j.neuint.2007.03.012
202. Shi, Q., Savage, J. E., Hufeisen, S. J., Rauser, L., Grajkowska, E., Ernsberger, P., et al. (2003). L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J. Pharmacol. Exp. Ther. 305, 131-142. doi: 10.1124/jpet.102.047092
203. Shin, J. Y., Fang, Z. H., Yu, Z. X., Wang, C. E., Li, S. H., and Li, X. J. (2005). Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171, 1001-1012. doi: 10.1083/jcb.200508072
204. Slow, E. J., Graham, R. K., Osmand, A. P., Devon, R. S., Lu, G., Deng, Y., et al. (2005). Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. U.S.A. 102, 11402-11407. doi: 10.1073/pnas.0503634102
205. Sönmez, A., Sayin, O., Gürgen, S. G., and Çalisir, M. (2015). Neuroprotective effects of MK-801 against traumatic brain injury in immature rats. Neurosci. Lett. 597, 137-142. doi: 10.1016/j.neulet.2015.05.001
206. Spencer, P. S., Nunn, P. B., Hugon, J., Ludolph, A. C., Ross, S. M., Roy, D. N., et al. (1987). Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237, 517-522. doi: 10.1126/science.3603037
207. Spooren, W., Lesage, A., Lavreysen, H., Gasparini, F., and Steckler, T. (2010). Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr. Top. Behav. Neurosci. 2, 391-413. doi: 10.1007/7854_2010_36
208. Stehberg, J., Moraga-Amaro, R., Salazar, C., Becerra, A., Echeverría, C., Orellana, J. A., et al. (2012). Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear memory consolidation in the basolateral amygdala. FASEB J. 26, 3649-3657. doi: 10.1096/fj.11-198416
209. Sun, Y., Savanenin, A., Reddy, P. H., and Liu, Y. F. (2001). Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713-24718. doi: 10.1074/jbc.M103501200
210. Takahashi, K., Kong, Q., Lin, Y., Stouffer, N., Schulte, D. A., Lai, L., et al. (2015). Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease. J. Exp. Med. 212, 319-332. doi: 10.1084/jem.20140413
211. Takamori, S. (2006). VGLUTs: 'exciting' times for glutamatergic research? Neurosci. Res. 55, 343-351. doi: 10.1016/j.neures.2006.04.016
212. Takeda, K., Ishida, A., Takahashi, K., and Ueda, T. (2012). Synaptic vesicles are capable of synthesizing the VGLUT substrate glutamate from alpha-ketoglutarate for vesicular loading. J. Neurochem. 121, 184-196. doi: 10.1111/j.1471-4159.2012.07684.x
213. Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S., et al. (2013). Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U.S.A. 110, E2518-E2527. doi: 10.1073/pnas.1306832110
214. Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe, M., Takahashi, K., et al. (1997). Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699-1702. doi: 10.1126/science.276.5319.1699
215. Thompson, M., Marecki, J. C., Marinesco, S., Labrie, V., Roder, J. C., Barger, S. W., et al. (2012). Paradoxical roles of serine racemase and D-serine in the G93A mSOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 120, 598-610. doi: 10.1111/j.1471-4159.2011.07601.x
216. Tong, J., Huang, C., Bi, F., Wu, Q., Huang, B., Liu, X., et al. (2013). Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 32, 1917-1926. doi: 10.1038/emboj.2013.122
217. Tsoi, H., and Chan, H. Y. (2014). Roles of the nucleolus in the CAG RNA-mediated toxicity. Biochim. Biophys. Acta 1842, 779-784. doi: 10.1016/j.bbadis.2013.11.015
218. Urenjak, J., and Obrenovitch, T. P. (2000). Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum. J. Neurochem. 75, 2427-2433. doi: 10.1046/j.1471-4159.2000.0752427.x
219. Vargas-Caballero, M., and Robinson, H. P. (2004). Fast and slow voltage-dependent dynamics of magnesium block in the NMDA receptor: the asymmetric trapping block model. J. Neurosci. 24, 6171-6180. doi: 10.1523/JNEUROSCI.1380-04.2004
220. Vécsei, L., Szalárdy, L., Fülöp, F., and Toldi, J. (2013). Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12, 64-82. doi: 10.1038/nrd3793
221. Vucic, S., Nicholson, G. A., and Kiernan, M. C. (2008). Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 131, 1540-1550. doi: 10.1093/brain/awn071
222. Wang, F., Smith, N. A., Xu, Q., Goldman, S., Peng, W., Huang, J. H., et al. (2013). Photolysis of caged Ca2+ but not receptor-mediated Ca2+ signaling triggers astrocytic glutamate release. J. Neurosci. 33, 17404-17412. doi: 10.1523/JNEUROSCI.2178-13.2013
223. Wang, X., Bao, X., Pal, R., Agbas, A., and Michaelis, E. K. (2010). Transcriptomic responses in mouse brain exposed to chronic excess of the neurotransmitter glutamate. BMC Genomics 11:360. doi: 10.1186/1471-2164-11-360
224. Watase, K., Hashimoto, K., Kano, M., Yamada, K., Watanabe, M., Inoue, Y., et al. (1998). Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. Eur. J. Neurosci. 10, 976-988. doi: 10.1046/j.1460-9568.1998.00108.x
225. Wolfensberger, M., Amsler, U., Cuénod, M., Foster, A. C., Whetsell, W. O. Jr., and Schwarcz, R. (1983). Identification of quinolinic acid in rat and human brain tissue. Neurosci. Lett. 41, 247-252. doi: 10.1016/0304-3940(83)90458-5
226. Wolosker, H., Sheth, K. N., Takahashi, M., Mothet, J. P., Brady, R. O. Jr., Ferris, C. D., et al. (1999). Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc. Natl. Acad. Sci. U.S.A. 96, 721-725. doi: 10.1073/pnas.96.2.721
227. Wu, Y. W., Grebenyuk, S., McHugh, T. J., Rusakov, D. A., and Semyanov, A. (2012). Backpropagating action potentials enable detection of extrasynaptic glutamate by NMDA receptors. Cell Rep. 1, 495-505. doi: 10.1016/j.celrep.2012.03.007
228. Xia, P., Chen, H. S., Zhang, D., and Lipton, S. A. (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 30, 11246-11250. doi: 10.1523/JNEUROSCI.2488-10.2010
229. Xing, X., Chang, L. C., Kong, Q., Colton, C. K., Lai, L., Glicksman, M. A., et al. (2011). Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg. Med. Chem. Lett. 21, 5774-5777. doi: 10.1016/j.bmcl.2011.08.009
230. Yamamoto, S., Morinobu, S., Iwamoto, Y., Ueda, Y., Takei, S., Fujita, Y., et al. (2010). Alterations in the hippocampal glycinergic system in an animal model of posttraumatic stress disorder. J. Psychiatr. Res. 44, 1069-1074. doi: 10.1016/j.jpsychires.2010.03.013
231. Yu, D., Tao, B. B., Yang, Y. Y., Du, L. S., Yang, S. S., He, X. J., et al. (2015). The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 43, 291-302. doi: 10.3233/JAD-140414
232. Yuzaki, M., and Connor, J. A. (1999). Characterization of L-homocysteate-induced currents in Purkinje cells from wild-type and NMDA receptor knockout mice. J. Neurophysiol. 82, 2820-2826.
233. Zeng, L. H., Ouyang, Y., Gazit, V., Cirrito, J. R., Jansen, L. A., Ess, K. C., et al. (2007). Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol. Dis. 28, 184-196. doi: 10.1016/j.nbd.2007.07.015
234. Zerangue, N., and Kavanaugh, M. P. (1996). Flux coupling in a neuronal glutamate transporter. Nature 383, 634-637. doi: 10.1038/383634a0
235. Zeron, M. M., Chen, N., Moshaver, A., Lee, A. T., Wellington, C. L., Hayden, M. R., et al. (2001). Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 17, 41-53. doi: 10.1006/mcne.2000.0909
236. Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., et al. (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860. doi: 10.1016/S0896-6273(02)00615-3
237. Zhou, X., Hollern, D., Liao, J., Andrechek, E., and Wang, H. (2013). NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis. 4, e560. doi: 10.1038/cddis.2013.82
238. Zhou, Y., and Danbolt, N. C. (2013). GABA and Glutamate Transporters in Brain. Front. Endocrinol. (Lausanne) 4:165. doi: 10.3389/fendo.2013.00165
239. Zhou, Y., and Danbolt, N. C. (2014). Glutamate as a neurotransmitter in the healthy brain. J. Neural. Transm. 121, 799-817. doi: 10.1007/s00702-014-1180-8
240. Zumkehr, J., Rodriguez-Ortiz, C. J., Cheng, D., Kieu, Z., Wai, T., Hawkins, C., et al. (2015). Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. Neurobiol. Aging 36, 2260-2271. doi: 10.1016/j.neurobiolaging.2015.04.005
241. Zwilling, D., Huang, S. Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H. Q., et al. (2011). Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874. doi: 10.1016/j.cell.2011.05.020